Science AI Journal
Medicine · Research topic

Open research questions in Systemic Lupus Erythematosus Research

56 unresolved questions extracted from the limitations and future-work sections of 431 Systemic Lupus Erythematosus Research papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • For further research, a larger sample size should be used, involving all SLE patients, both inpatients and outpatients, to ensure a more representative sample and provide a more comprehensive picture of patient conditions. Furthermore, research can utilize an analytical design and include immunological testing variables, such as ANA and/or anti-dsDNA, to support assessments of disease activity and patient characteristics. The date of each laboratory test should also be recorded to evaluate the timing of the test and the assessment of disease activity, enhancing the validity of the research data. REFERENCES Adhikari K, Karki H, Shrestha P, Sigdel KR, Sharma L, Paudel BP. Hematological manifestations in systemic lupus erythematosus: a retrospective cross-sectional study from a tertiary care center in Nepal. Annals of Medicine & Surgery. 2025 Oct;87(10):6335– 9. doi:10.1097/ms9.0000000000003765 Aflaki M, Bargman JM. Urine Protein Tests in Systemic Lupus Erythematosus: What Do They Mean? Journal of Rheumatology. Journal of Rheumatology; 2025. p. 308–15. doi:10.3899/jrheum.2024-0910 PubMed PMID: 39892881. Akbarian M, Soleymani H, Gharibdoost F, Nadji A, Jamshidi A, Shahram F, et al. Isolated Hematuria in SLE Patients and Its Association with Proteinuria, Urinary Cast and SLE Disease Activity. Acta Medica Iranica. 2009. Alhussain AH, Alquwayi WA, Alkuwaiti YAA, Almehainy AM, Alkhathami Adel Ahmed. Laboratory assessment of systemic lupus erythematosus. Int J Health Sci (Qassim). 2020 May 18;4(S1):248–68. doi:10.53730/ijhs.v4nS1.15215 Anindito B, Hidayat R, Koesnoe S, Dewiasty E. Validity and Reliability of Lupus Quality of Life Questionnaire in Patients with Systemic Lupus Erythematosus in Indonesia. Indonesian Journal of Rheumatology. 2016. Jurnal Ilmu Psikologi Dan Kesehatan Vol.03 No.

    Description of Laboratory Examination Results of Systemic Lupus Erythematosus (SLE) Patients Based on Mex-SLEDAI Levels at Raden Mattaher Hospital Jambi · 2026 · DOI

  • Abstract Background The correlation between self-esteem and sexual function in systemic lupus erythematosus (SLE) patients remains unexplored.

    Self-esteem as a determinant of sexual function in systemic lupus erythematosus patients: a cross-sectional study · 2026 · DOI

  • RNA-binding protein LARP4 plays an important role in T cell activation and differentiation, but its role in B cell biology and the pathogenesis of systemic lupus erythematosus (SLE) remains unclear.

    LARP4 is a B cell-specific metabolic checkpoint for plasma cell differentiation and a therapeutic target in systemic lupus erythematosus · 2026 · DOI

  • While autosomal dominant A20 mutations have been identified to cause autoinflammatory disease, recessive A20 mutations causing disease have not been previously described.

    Autosomal recessive A20 zinc finger 7 mutation is associated with early-onset lupus-like disease · 2026 · DOI

  • This observation supports previous reports suggesting that rituximab may serve as an effective therapeutic option for refractory BSLE, particularly when conventional therapy is insufficient.

    Refractory bullous systemic lupus erythematosus in a 14-year-old girl successfully treated with low-dose rituximab: A case report · 2026 · DOI

  • Future research involving a larger cohort of individuals with SNAPS is necessary to assess the true diagnostic utility of these markers. The persistence of antibodies (>12 weeks) cannot be assessed owing to the cross-sectional nature of this study. This study did not include healthy controls or disease controls, which would have helped establish the specificity of non-criteria antibodies or define strict cutoffs for a positive diagnosis. The testing for non-criteria antibodies is not standardized, and the dot-blot technique used in this study may vary compared with other techniques. Therefore, before considering the incorporation of these antibodies into routine APS screening, subsequent studies must rigorously address the methodological constraints identified here.

    Expanding the diagnostic horizon of anti-phospholipid syndrome: impact of non-criteria anti-phospholipid antibodies · 2026 · DOI

  • The concurrent use of DMARDs and hematologic malignancy treatments in SLE patients requires careful individualization, as direct evidence remains scarce. Particular vigilance is warranted when cytopenias prove refractory to standard SLE therapy, when B symptoms occur disproportionate to serologic disease activity, or when lymphadenopathy is persistent and atypical in distribution.

    Hematological malignancies and autoimmune hemolytic anemia in systemic lupus erythematosus patients: A literature review · 2026 · DOI

  • limits Our study contributes to the limited literature on SLE patients’ thoughts about pregnancy, but also has several limitations. The study included a relatively limited number of patients, which the generalizability of the results. Further studies with larger sample groups could improve the accuracy of the results. However, the inclusion of retrospective data (e.g., information on pregnancy) and some activity, patient-reported contraceptive use) makes it difficult to fully establish causal relationships. The socio-cultural characteristics of the patients, their psychosocial status and their level of education in relation to pregnancy planning were not investigated in detail. The impact of these factors on disease management and pregnancy thoughts needs to be investigated more comprehensively. disease (e.g., data Researcher Contribution Statement: Idea and design: S.P., B.N.K.K., R.G.Y.S., B.Y., E.D., Y.P.; Data collection and processing: S.P., B.N.K.K., R.G.Y.S., B.Y.; Analysis and interpretation of data: S.P., B.N.K.K., R.G.Y.S., B.Y., Y.P.; Writing of significant parts of the article: S.P., B.N.K.K., R.G.Y.S., B.Y., E.D., Y.P.

    Thoughts on Fertility and Pregnancy in Patients with Systemic Lupus Erythematosus · 2026 · DOI

  • MxA is an important downstream effector of IFN-I pathway and may be useful for SLE diagnosis and treatment. The biomarker is highly expressed in PBMC of SLE patients and in the kidney tissues of LN patients, and may change as the disease activity changes. Depending on the response it could respond to treatment. Clinical applications still require standards of detection, avoidance of interfering factors, popularization on the up-level. In future, speed and standards of diagnosis should be accelerated, detection norms and key values should be made unified, MxA combined with IFN-α, IL-6, etc. might be effective in predicting diagnosis and prognosis; MxA might be a therapeutic target; large-sample multi-center prospective studies could clarify limits and application limits on early diagnosis, prognosis, treatment, and SLE. As standardized detection, multiple markers, large-scale studies continue, MxA will be a biomarker across SLE from early screening and disease monitor to a precise treatment, to further improvement of SLE diagnosis and Treatment at an individual level and quantitative level.

    Myxovirus Resistance Protein A (MxA) in Systemic Lupus Erythematosus: A Review of Recent Advances in Diagnosis and Disease Management · 2026 · DOI

  • The strengths of this case series lie in the clinical authenticity of the three cases, their representation of a genuinely broad spectrum of SLE obstetric complexity, and the multidisciplinary nature of the decision-making described. The series provides a real-world counterpart to population-level data from risk systematic estimates in concrete clinical narratives. Limitations include the small number of cases (inherent to the case series design), the absence of long-term reviews, grounding abstract disease-related by but that that despite overwhelming, maternal renal follow-up data in Cases 1 and 2, and the reliance on clinical diagnosis of lupus nephritis in Case 2 without histological confirmation. PATIENT PERSPECTIVE All three patients expressed gratitude for the they received sustained and coordinated care throughout their hospital admissions. The patient in Case 1 conveyed the fear and uncertainty surrounding the emergency surgery and the haemorrhagic complication, she felt reassured by the clarity with which each intervention was explained to her and her family. She emphasised that being kept informed at every step was central to her sense of safety. The patient in Case 2 shared that the experience of managing a complex twin pregnancy alongside a new autoimmune diagnosis was emotionally early counselling about disease management and fetal surveillance helped her to understand the nature of the risks involved. She expressed relief at the delivery of her twins alive and appreciated the close postpartum support provided. The patient in Case 3, in her own words, described the experience of being told that continuing her pregnancy would place her life at serious risk as profoundly difficult. She expressed that she was treated with dignity and compassion throughout the counselling process and acknowledged that, with hindsight, she understood the reasoning behind the decision for termination of pregnancy, even as she continued to grieve the loss.

    Spectrum of Pregnancy Outcomes in Systemic Lupus Erythematosus: A Three-Case Series Highlighting Diagnostic and Therapeutic Challenges · 2026 · DOI

  • Abstract Introduction The precise nature of dermatomyositis (DM) and systemic lupus erythematosus (SLE) is not yet fully understood, although it is recognized that various genetic, hormonal or external factors play a significant role in the onset of autoimmune processes.

    Association of OSMR Gene Variants rs2278329 and rs2292016 with Dermatomyositis and Systemic Lupus Erythematosus in Bulgarian Patients · 2026 · DOI

  • Background Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease influenced by complex metabolic and inflammatory pathways, but the impact of specific metabolic and inflammatory signatures, particularly metabolic vulnerability index (MVX), inflammation vulnerability index (IVX), and metabolic malnutrition index (MMX), on the incidence of SLE remains unclear.

    Association of metabolic and inflammation vulnerabilities with systemic lupus erythematosus: a prospective UK Biobank study · 2026 · DOI

  • Second, the widespread use of low-dose aspirin (LDA) for pre-eclampsia prophylaxis in high-risk pregnancies may have confounded the results [30]; LDA was commonly used across studies but was rarely stratified or adequately adjusted for in analyses, and the inability to disentangle its independent effect from that of HCQ represents a major limitation.

    The influence of hydroxychloroquine on the risk of pre-eclampsia, hypertension, and premature delivery in patients with systemic lupus erythematosus during pregnancy: a meta-analysis · 2026 · DOI

  • Several limitations of this meta-analysis should be con- sidered. First, all included studies were observational, and despite generally high NOS scores, they remain susceptible to residual confounding by indication, disease activity, and concomitant medications. Second, we were unable to adjust for major confounders such as lupus nephritis, antiphospho- lipid syndrome, baseline disease activity, or low-dose aspirin use, as these were not consistently reported. Third, selection bias related to parity may have influenced the results, par- ticularly among multiparous women. Fourth, information on HCQ dosing was limited, and weight-based dose adjust- ments during pregnancy were not recorded. Fifth, none of the included studies monitored HCQ blood concentrations, precluding quantification of true drug exposure. Finally, according to the GRADE framework, the overall certainty of evidence for all outcomes was low to very low. To address these limitations, well-designed prospective studies are needed. Future research should prioritize stan- dardized reporting of key confounders, detailed data on HCQ dosing and adherence, and parity-stratified outcomes. Large, well-conducted prospective cohort studies with rig- orous adjustment for confounders—including propensity score methods—may provide the most feasible approach to advancing understanding in this area.

    The influence of hydroxychloroquine on the risk of pre-eclampsia, hypertension, and premature delivery in patients with systemic lupus erythematosus during pregnancy: a meta-analysis · 2026 · DOI

  • The pathogenesis of SLE is driven by multifaceted dysregulation across both adaptive and innate immunity, with aberrant T and B cell activation playing a central role (Figure 6). Expansion of Th17 and Tfh subsets, coupled with impaired Treg function, promotes sustained inflammation and high-affinity autoantibody production, ultimately leading to immune complex deposition and tissue damage (59, 236). T cell metabolic abnormalities—such as elevated glycolysis and mitochondrial dysfunction—not only sustain pathological activation but also provide actionable targets for metabolic intervention (e.g., mTOR inhibitors, glycolysis blockers) (41). Additionally, T and B cells form a pathogenic feedback loop via CD40–CD40L and IL-21 signaling, exacerbated by deficient Bregmediated regulation, underscoring the need to restore immune tolerance (237). Innate immune dysregulation further amplifies disease. Persistent IFN-a production by pDCs via TLR7/9, M1- biased macrophage polarization, defective apoptotic clearance, and mitochondrial ROS accumulation collectively fuel chronic inflammation (11, 15). Excessive NETosis and LDG accumulation expose nuclear autoantigens, augmenting autoantibody responses and damaging endothelium, particularly in lupus nephritis (20). Impaired NK cytotoxicity and cytokine imbalance hinder clearance of autoreactive cells, destabilizing immune homeostasis (25). Emerging evidence has established gut microbiome dysbiosis as a key environmental factor contributing to immune dysregulation in SLE. Gut microbiome dysbiosis, characterized by depletion of butyrate-producing bacteria and enrichment of pro-inflammatory taxa such as Ruminococcus gnavus, further contributes to immune dysregulation through gut barrier dysfunction, molecular mimicry, and SCFA deficiency (200, 238). Current treatment of SLE follows a treat-to-target strategy, combining universal background therapy with hydroxychloroquine, judicious glucocorticoid use, and steroid-sparing immunosuppressants such as mycophenolate mofetil, azathioprine, and cyclophosphamide, selected according to disease severity and organ involvement (239). Among these, hydroxychloroquine remains foundational due to its ability to reduce disease activity, prevent flares, and provide long-term vascular protection (240). The growing understanding of SLE pathogenesis has guided the development of targeted biologics.

    The landscape of cellular immune alteration in systemic lupus erythematosus · 2026 · DOI

  • Representative references SNPs, GWAS, polygenic risk scores Risk prediction, susceptibility gene prioritization, ancestry stratification Identifies inherited risk structure and susceptibility loci; useful for baseline risk…

    Applications of artificial intelligence in systemic lupus erythematosus: integrating multi-omics data for precision medicine · 2026 · DOI

  • This topic remains poorly studied, so there is an important problem in developing high-quality research that allow a better understanding of the anesthetic consequences of SLE with the creation of appropriate clinical protocols; facilitate the management of these patients; optimize the safety of anesthesia; reduce the rate of complications and associated mortality.

    Anesthetic problems in concomitant systemic lupus erythematosus (literature review) · 2025 · DOI

  • Furthermore, no reports have previously confirmed elevated CA 125 levels with lupus-related protein-losing enteropathy or increased 99mTc-HSA activity with pseudo-pseudo Meigs' syndrome.

    Lupus-related protein-losing enteropathy associated with pseudo-pseudo Meigs’ syndrome and successfully treated with hydroxychloroquine · 2021 · DOI

  • Previously reported cases have been described as being caused by either pseudo-Meigs's syndrome or lupus-related protein-losing enteropathy as the cause of the rare pathology that causes marked pleural effusion and ascites in patients with systemic lupus erythematosus, but it has not been evaluated whether the other is co-occurring.

    Lupus-related protein-losing enteropathy associated with pseudo-pseudo Meigs’ syndrome and successfully treated with hydroxychloroquine · 2021 · DOI

  • Background/Objectives: Repeat kidney biopsy in lupus nephritis is increasingly used to resolve discrepancies between clinical, serological and histological findings, but its diagnostic yield in real-world practice remains incompletely defined.

    Repeat Kidney Biopsy in Lupus Nephritis: Diagnostic Yield and Clinical Utility in a Real-World Single-Centre Cohort · 2026 · DOI

  • Another rarely reported aspect of this case is the presence of multifocal AVN involving the humeral head, distal femur, and proxi- mal tibia.

    Successful rituximab therapy in refractory systemic lupus erythematosus with multi-organ involvement: a case report · 2026 · DOI

  • SLE as a potential risk factor for glaucoma has attracted attention, but existing study conclusions remain controversial.

    The risk association between systemic lupus erythematosus and glaucoma: a systematic review and meta-analysis · 2026 · DOI

  • There is limited data on tubulointerstitial inflammation (TII) and tubulointerstitial damage (TID) in Middle Eastern populations.

    Forgotten compartment: Impact of tubulointerstitial inflammation and damage on renal outcomes in lupus nephritis from Saudi Arabia · 2026 · DOI

  • Some results showed wide confidence intervals (CIs), which could indicate instability in the model, especially for the anxiety variable, suggesting the need for further refinement of the model to improve accuracy and stability of estimates.

    Association between corticosteroid dosage and symptoms of depression and anxiety in patients with systemic lupus erythematosus · 2025 · DOI

  • Thus, further studies of familial autoimmunity will help in in- creasing the knowledge about the common mecha- nisms of autoimmunity (17).

    General characteristics and familial aggregation in patients with systemic lupus erythematosus · 2018 · DOI

Most-cited papers in Systemic Lupus Erythematosus Research

Most recent work

Find a gap in your own Systemic Lupus Erythematosus Research sub-topic

This page shows what the Systemic Lupus Erythematosus Research literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
56 open questions have been extracted from the limitations and future-work passages of 431 Systemic Lupus Erythematosus Research papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.